Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronidazole and Chlorhexidine in Oral Cancer
NCT06627270Phase 2Recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jul 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metronidazole and chlorhexidine + cymenol gel in oral squamous cell carcinoma (OSCC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Change in absolute amount of intratumoral bacteria as quantified by 16S rRNA qPCR at 10 days. Started Jul 2025; status: recruiting.
02
Drugs
metronidazolechlorhexidine + cymenol gel
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT06627270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627270.